Sleep disorders in patients with cancer

Journal of Community and Supportive Oncology

Volumn 13, Issue 4, 2015, Pages 148-155

  Guzman Marin, Ruben ^a   Avidan, Alon Y ^b  

^a LOS ANGELES MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER PATIENT; CIRCADIAN RHYTHM SLEEP DISORDER; CONCEPTUAL FRAMEWORK; DISEASE MANAGEMENT; FATIGUE; HUMAN; HYPERSOMNIA; INSOMNIA; PARASOMNIA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESTLESS LEGS SYNDROME; REVIEW; SLEEP DISORDER; SLEEP DISORDERED BREATHING;

EID: 84991777297     PISSN: 23307749     EISSN: None     Source Type: Journal    
DOI: 10.12788/jcso.0126     Document Type: Review

References (68)

1. Ehlers CL, Frank E, Kupfer DJ. Social zeitgebers and biological rhythms: A unified approach to understanding the etiology of depression. Arch Gen Psych. 1988;45: 948.
2. Davidson JR, MacLean AW, Brundage MD, Schulze K. Sleep disturbance in cancer patients. Soc Sci Med. 2002;54: 1309-1321.
3. American Academy of Sleep Medicine. International classification of sleep disorders, 3rd ed. Darien, IL: American Academy of Sleep Medicine, 2014.
4. Berglund G, Bolund C, Fornander T, Rutqvist LE, Sj P-O. Late effects of adjuvant chemotherapy and postoperative radiotherapy on quality of life among breast cancer patients. Eur J Cancer Clin Oncol. 1991;27: 1075-1081.
5. Dow KH, Ferrell BR, Leigh S, Ly J, Gulasekaram P. An evaluation of the quality of life among long-term survivors of breast cancer. Breast Cancer Res Treat. 1996;39: 261-273.
6. Young T, Palta M, Dempsey J, Skatrud J, Weber S, Badr S. The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med. 1993;328: 1230-1235.
7. Karatas M. Restless legs syndrome and periodic limb movements during sleep: Diagnosis and treatment. Neurologist. 2007;13: 294-301.
8. Savard J, Morin CM. Insomnia in the context of cancer: A review of a neglected problem. J Clin Oncol. 2001;19: 895-908.
9. Palesh OG, Roscoe JA, Mustian KM, et al. Prevalence, demographics, and psychological associations of sleep disruption in patients with cancer: University of Rochester Cancer Center-Community Clinical Oncology Program. J Clin Oncol. 2010;28: 292-298.
10. Vena C, Parker K, Cunningham M, Clark J, McMillan S. Sleep-wake disturbances in people with cancer part I: An overview of sleep, sleep regulation, and effects of disease and treatment. Oncol Nurs Forum. 2004;13;31: 747-71.
11. Clark J, Cunningham M, McMillan S, Vena C, Parker K. Sleep-wake disturbances in people with cancer part II: Evaluating the evidence for clinical decision making. Oncol Nurs Forum. 2004; 13;31: 747- 71
12. Spielman AJ, Caruso LS, Glovinsky PB. A behavioral perspective on insomnia treatment. Psychiatr Clin North Am. 1987: 10: 541-53.
13. Woodward SC. Cognitive-behavioral therapy for insomnia in patients with cancer. Clin J Oncol Nurs. 2011;15: E42-E52.
14. Graci G. Pathogenesis and management of cancer-related insomnia. J Support Oncol. 2005;3: 349-359.
15. Kvale EA, Shuster JL. Sleep disturbance in supportive care of cancer: A review. J Palliat Med. 2006;9: 437-450.
16. Parker KP, Bliwise DL, Ribeiro M, et al. Sleep/wake patterns of individuals with advanced cancer measured by ambulatory polysomnography. J Clin Oncol. 2008;26: 2464-2472.
17. Barsevick AM, Cleeland CS, Manning DC, et al. ASCPRO recommendations for the assessment of fatigue as an outcome in clinical trials. J Pain Symptom Manage. 2010;39: 1086-1099.
18. O'Donnell JF. Insomnia in cancer patients. Clin Cornerstone. 2004;6: S6-S14.
19. Hu D-S, Silberfarb P. Management of sleep problems in cancer patients. Oncology (Williston Park, NY). 1991;5: 23.
20. Griffiths RR, Johnson MW. Relative abuse liability of hypnotic drugs: A conceptual framework and algorithm for differentiating among compounds. J Clin Psych. 2005;66(suppl 9): 31-41.
21. Doghramji PP. Trends in the pharmacologic management of insomnia. J Clin Psych. 2006;67: 5-8.
22. Berger AM. Update on the state of the science: Sleep-wake disturbances in adult patients with cancer. Oncol Nurs Forum. 2009;36: E165-77.
23. Berger AM, Abernethy AP, Atkinson A, et al. Cancer-related fatigue. J Natl Compr Canc Netw. 2010;8: 904-931.
24. Armstrong TS, Cron SG, Bolanos EV, Gilbert MR, Kang DH. Risk factors for fatigue severity in primary brain tumor patients. Cancer. 2010;116: 2707-2715.
25. Lovely MP, Miaskowski C, Dodd M. Relationship between fatigue and quality of life in patients with glioblastoma multiformae. Oncol Nurs Forum. 1999;26: 921-25.
26. Miaskowski C. Gender differences in pain, fatigue, and depression in patients with cancer. JNCI Monographs. 2004;32: 139-143.
27. Manley PE, McKendrick K, McGillicudy M, et al. Sleep dysfunction in long term survivors of craniopharyngioma. J Neurooncol. 2012;108: 543-549.
28. Drappatz J, Schiff D, Kesari S, Norden AD, Wen PY. Medical management of brain tumor patients. Neurol Clin. 2007;25: 1035-1071.
29. Struik K, Klein M, Heimans JJ, et al. Fatigue in low-grade glioma. J Neurooncol. 2009;92: 73-78.
30. Beisecker AE, Cook MR, Ashworth J, et al. Side effects of adjuvant chemotherapy: Perceptions of node-negative breast cancer patients. Psycho-oncology. 1997;6: 85-93.
31. Mendoza TR, Wang XS, Cleeland CS, et al. The rapid assessment of fatigue severity in cancer patients. Cancer. 1999;85: 1186-1196.
32. Guidelines NNCCN. 2012 Cancer-Related Fatigue. In: NCCN, ed. Fort Washington, PA2011.
33. Hayashi M, Watanabe M, Hori T. The effects of a 20 min nap in the mid-afternoon on mood, performance and EEG activity. Clin Neurophysiol. 1999;110: 272-279.
34. Moraska AR, Sood A, Dakhil SR, et al. Phase III, randomized, double- blind, placebo-controlled study of long-acting methylphenidate for cancer-related fatigue: North Central Cancer Treatment Group NCCTG-N05C7 trial. J Clin Oncol. 2010;28: 3673-3679.
35. Minton O, Richardson A, Sharpe M, Hotopf M, Stone PC. Psychostimulants for the management of cancer-related fatigue: A systematic review and meta-analysis. J Pain Symptom Manage. 2011;41: 761-767.
36. Gehring K, Patwardhan S, Collins R, et al. A randomized trial on the efficacy of methylphenidate and modafinil for improving cognitive functioning and symptoms in patients with a primary brain tumor. J Neurooncol. 2012;107: 165-174.
37. Caples SM, Gami AS, Somers VK. Obstructive sleep apnea. Ann Intern Med. 2005;142: 187-197.
38. Young T, Skatrud J, Peppard PE. Risk factors for obstructive sleep apnea in adults. JAMA. 2004;291: 2013-2016.
39. Bassetti C, Aldrich MS. Sleep apnea in acute cerebrovascular diseases: Final report on 128 patients. Sleep. 1999;22: 217-224.
40. Nieto FJ, Peppard PE, Young T, Finn L, Hla KM, FarrR. Sleepdisordered breathing and cancer mortality: Results from the Wisconsin Sleep Cohort Study. Am J Respir Crit Care Med. 2012;186: 190-194.
41. Campos-Rodriguez F, Martinez-Garcia MA, Martinez M, et al. Association between obstructive sleep apnea and cancer incidence in a large multicenter Spanish cohort. Am J Respir Crit Care Med. 2013;187: 99-105.
42. Friedman M, Landsberg R, Pryor S, Syed Z, Ibrahim H, Caldarelli DD. The occurrence of sleep-disordered breathing among patients with head and neck cancer. Laryngoscope. 2001;111: 1917-1919.
43. Rombaux P, Hamoir M, Plouin-Gaudon I, Liistro G, Aubert G, Rodenstein D. Obstructive sleep apnea syndrome after reconstructive laryngectomy for glottic carcinoma. Eur Arch Otorhinolaryngol. 2000;257: 502-506.
44. Broman JE, Mallon L, Hetta J. Restless legs syndrome and its relationship with insomnia symptoms and daytime distress: Epidemiological survey in Sweden. Psychiatry Clin Neurosci. 2008;62: 472-475.
45. Arico D, Raggi A, Siragusa M, Zucconi M, Ferri R. Restless legs syndrome as the presenting symptom of multiple myeloma. J Clin Sleep Med. 2012;9: 383-385.
46. Ostacoli L, Saini A, Ferini-Strambi L, et al. Restless legs syndrome and its relationship with anxiety, depression, and quality of life in cancer patients undergoing chemotherapy. Qual Life Res. 2010;19: 531-537.
47. Forsythe LP, Helzlsouer KJ, MacDonald R, Gallicchio L. Daytime sleepiness and sleep duration in long-term cancer survivors and noncancer controls: Results from a registry-based survey study. Support Care Cancer. 2012;20: 2425-2432.
48. Armstrong TS, Gilbert MR. Practical strategies for management of fatigue and sleep disorders in people with brain tumors. Neuro Oncol. 2012;14: Iv65-iv72.
49. Gapstur R, Gross CR, Ness K. Factors associated with sleep-wake disturbances in child and adult survivors of pediatric brain tumors: A review. Oncol Nurs Forum. 2009;36: 723-31.
50. Rosenfeld MR, Eichen JG, Wade DF, Posner JB, Dalmau J. Molecular and clinical diversity in paraneoplastic immunity to Ma proteins. Ann Neurol. 2001;50: 339-348.
51. Elrington G, Murray N, Spiro S, Newsom-Davis J. Neurological paraneoplastic syndromes in patients with small cell lung cancer. A prospective survey of 150 patients. Neurol Neurosurg Psychiatry. 1991;54: 764-767.
52. Mahowald MW, Ettinger MG. Things that go bump in the night: The parasomnias revisited. J Clin Neurophysiol. 1990;7: 119-144.
53. Boeve B, Silber M, Saper C, et al. Pathophysiology of REM sleep behaviour disorder and relevance to neurodegenerative disease. Brain. 2007;130: 2770-2788.
54. Jianhua C, Xiuqin L, Quancai C, Heyang S, Yan H. Rapid eye movement sleep behavior disorder in a patient with brainstem lymphoma. Intern Med. 2012;52: 617-621.
55. Adams C, McKeon A, Silber MH, Kumar R. Narcolepsy, REM sleep behavior disorder, and supranuclear gaze palsy associated with Ma1 and Ma2 antibodies and tonsillar carcinoma. Arch Neurol. 2011;68: 521-524.
56. Shinno H, Kamei M, Maegawa T, et al. Three patients with cancer who developed rapid-eye-movement sleep behavior disorder. J Pain Symptom Manage. 2010;40: 449-452.
57. Standards of Practice Committee, Aurora RN, Zak RS, et al. Best practice guide for the treatment of REM sleep behavior disorder (RBD). J Clin Sleep Med. 2010;6: 85-95.
58. Davis S, Mirick DK. Circadian disruption, shift work and the risk of cancer: A summary of the evidence and studies in Seattle. Cancer Causes Control. 2006;17: 539-545.
59. Arendt J. Shift work: Coping with the biological clock. Occup Med. 2010;60: 10-20.
60. Thomas CR, Reiter RJ, Herman TS. Melatonin: From basic research to cancer treatment clinics. J Clin Oncol. 2002;20: 2575-2601.
61. Schernhammer ES, Berrino F, Krogh V, et al. Urinary 6-Sulphatoxymelatonin levels and risk of breast cancer in premenopausal women: The ORDET cohort. Cancer Epidemiol Biomarkers Prev. 2010;19: 729-737.
62. Gallicchio L, Kalesan B. Sleep duration and mortality: A systematic review and meta-analysis. J Sleep Res. 2009;18: 148-158.
63. Mazzoccoli G, Vendemiale G, De Cata A, Carughi S, Tarquini R. Altered time structure of neuro-endocrine-immune system function in lung cancer patients. BMC Cancer. 2010;10: 314.
64. Hrushesky WJ, Grutsch J, Wood P, et al. Circadian clock manipulation for cancer prevention and control and the relief of cancer symptoms. Integr Cancer Ther. 2009;8: 387-397.
65. Mormont M-C, Waterhouse J, Bleuzen P, et al. Marked 24-h rest/ activity rhythms are associated with better quality of life, better response, and longer survival in patients with metastatic colorectal cancer and good performance status. Clin Cancer Res. 2000;6: 3038-3045.
66. Mormont M, Levi F. Circadian-system alterations during cancer processes: A review. Int J Cancer. 1997;70: 241-247.
67. Sephton S, Spiegel D. Circadian disruption in cancer: A neuroendocrine- immune pathway from stress to disease? Brain Behav Immun. 2003;17: 321-328.
68. Eismann EA, Lush E, Sephton SE. Circadian effects in cancer-relevant psychoneuroendocrine and immune pathways. Psychoneuroendocrinology. 2010;35: 963-976.